RASON, a new player in cancer's Premier League.
作者信息
Mainardi Sara, Bernards Rene
机构信息
Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
出版信息
Cell Res. 2023 Jan;33(1):1-2. doi: 10.1038/s41422-022-00750-7.
Abstract
摘要
相似文献
1
RASON, a new player in cancer's Premier League.RASON，癌症“超级联赛”中的新成员。
Cell Res. 2023 Jan;33(1):1-2. doi: 10.1038/s41422-022-00750-7.
2
Trigger found that may start cancer's spread. Research may lead to new therapies to halt cancer's progression.发现可能引发癌症扩散的触发因素。该研究可能会带来阻止癌症进展的新疗法。
Duke Med Health News. 2010 May;16(5):1-2.
3
A novel protein RASON encoded by a lncRNA controls oncogenic RAS signaling in KRAS mutant cancers.一种由长链非编码 RNA 编码的新型蛋白 RASON 控制 KRAS 突变型癌症中的致癌 RAS 信号。
Cell Res. 2023 Jan;33(1):30-45. doi: 10.1038/s41422-022-00726-7. Epub 2022 Oct 14.
4
New Player in Cancer's Spread.癌症扩散的新因素
Sci Am. 2020 Oct 1;323(4):28. doi: 10.1038/scientificamerican1020-28.
5
Obesity: an heavyweight player in breast cancer's chemoresistance.肥胖：乳腺癌化疗耐药中的一个重要因素。
Oncotarget. 2019 May 14;10(35):3207-3208. doi: 10.18632/oncotarget.26905.
6
Unmasking SMLR1: The hidden player in colorectal cancer's liver metastasis.揭开SMLR1的面纱：结直肠癌肝转移中的隐藏角色。
Cancer Heterog Plast. 2024;1(1). doi: 10.47248/chp2401010002. Epub 2024 Jul 18.
7
Modeling the impact of players' workload on the injury-burden of English Premier League football clubs.建立模型，以评估球员工作量对英超足球俱乐部伤病负担的影响。
Scand J Med Sci Sports. 2018 Jun;28(6):1715-1721. doi: 10.1111/sms.13078. Epub 2018 Mar 9.
8
Differences in Technical Performance of Players From 'The Big Five' European Football Leagues in the UEFA Champions League.来自欧洲“五大”足球联赛的球员在欧洲冠军联赛中的技术表现差异。
Front Psychol. 2019 Dec 6;10:2738. doi: 10.3389/fpsyg.2019.02738. eCollection 2019.
9
Effect of a new concussion substitute rule on medical assessment of head collision events in Premier League football.新脑震荡替代规则对英超足球头部碰撞事件医疗评估的影响。
Inj Prev. 2022 Dec;28(6):521-525. doi: 10.1136/ip-2022-044580. Epub 2022 Jul 5.
10
New insights into cancer's exploitation of platelets.癌症利用血小板的新见解。
J Thromb Haemost. 2019 Dec;17(12):2000-2003. doi: 10.1111/jth.14624.
引用本文的文献
1
Epigenomic exploration of disease status of EGFR-mutated non-small cell lung cancer using plasma cell-free DNA hydroxymethylomes.利用血浆游离DNA羟甲基化组对表皮生长因子受体（EGFR）突变的非小细胞肺癌疾病状态进行表观基因组学探索。
Cancer Commun (Lond). 2025 Jan;45(1):51-55. doi: 10.1002/cac2.12606. Epub 2024 Nov 11.
本文引用的文献
1
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.在携带有突变的非小细胞肺癌中使用阿达格拉西布。
N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3.
2
Acquired Resistance to KRAS Inhibition in Cancer.癌症中对 KRAS 抑制的获得性耐药。
N Engl J Med. 2021 Jun 24;384(25):2382-2393. doi: 10.1056/NEJMoa2105281.
3
Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
4
RAS-targeted therapies: is the undruggable drugged?RAS 靶向治疗：无药可治的靶点被攻克了？
Nat Rev Drug Discov. 2020 Aug;19(8):533-552. doi: 10.1038/s41573-020-0068-6. Epub 2020 Jun 11.
5
The translation of non-canonical open reading frames controls mucosal immunity.非规范开放阅读框的翻译控制黏膜免疫。
Nature. 2018 Dec;564(7736):434-438. doi: 10.1038/s41586-018-0794-7. Epub 2018 Dec 12.
6
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.SHP2 对于体内 KRAS 突变型非小细胞肺癌的生长是必需的。
Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.
7
Drugging the undruggable RAS: Mission possible?靶向不可成药的 RAS：可能完成的任务？
Nat Rev Drug Discov. 2014 Nov;13(11):828-51. doi: 10.1038/nrd4389. Epub 2014 Oct 17.
8
Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.帕尼单抗联合 FOLFOX4 治疗与结直肠癌的 RAS 突变。
N Engl J Med. 2013 Sep 12;369(11):1023-34. doi: 10.1056/NEJMoa1305275.
9
RAS oncogenes: the first 30 years.RAS致癌基因：最初的30年。
Nat Rev Cancer. 2003 Jun;3(6):459-65. doi: 10.1038/nrc1097.
Zotero 插件